Naringin alleviates gefitinib-induced hepatotoxicity through anti-oxidation, inhibition of apoptosis, and autophagy

Articles in Press

Document Type : Original Article

Authors

Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Department of Basic Medicine, Chongqing Three Gorges Medical College, Chongqing 404120, China

10.22038/ijbms.2024.76852.16623

Abstract

Objective(s): Gefitinib (GEF) is a targeted medicine used to treat locally advanced or metastatic non-small cell lung cancer (NSCLC). However, GEF’s hepatotoxicity limits its clinical use. This study aims to investigate the protective effect of naringin (NG) against GEF-induced hepatotoxicity. 
Materials and Methods: Fifty female ICR mice were randomly divided into 5 groups: Control, GEF (200 mg/kg), NG (50 mg/kg) + GEF (200 mg/kg), NG (100 mg/kg) +GEF (200 mg/kg), NG (200 mg/kg) +GEF (200 mg/kg). After 4 weeks of continuous administration, the mice were euthanized. The blood and liver tissue samples were collected. 
Results: The results indicated that the GEF group showed increased liver index, liver enzyme activities, and decreased glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) activities. Some hepatocytes showed hydropic degeneration and focal necrosis. Cell apoptosis, Cleaved-caspase3, and Poly (ADP-ribose) polymerase 1 (PARP1) increased. Transmission electron microscopy revealed the presence of numerous autophagic lysosomes or autophagosomes around the cell nucleus. Compared to the GEF group, NG can reverse these changes. 
Conclusion: In summary, NG alleviates GEF-induced hepatotoxicity by anti-oxidation, inhibiting cell apoptosis, and autophagy. Therefore, this study suggests the use of NG to mitigate GEF’s toxicity to the liver.

Keywords

Main Subjects

References

1. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-1043.
2. Qian J, Zhang X, Zhang B, Yan B, Wang L, Gu P, et al. Tyrosine kinase inhibitor-related hepatotoxicity in patients with advanced lung adenocarcinoma: a real-world retrospective study. Cancer Manag Res 2020; 11:12:3293-3299.
3. Kwok WC, Lam DCL, Ip MSM, Ho JCM. Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities. Anticancer Drugs 2022; 33:1139-1144.
4. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11:121-128.
5. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-2388.
6. Ueda H, Hayashi H, Kudo K, Takeda M, Nakagawa K. Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity. Invest New Drugs 2016; 34:797-799. 
7. Li J, Wang L. Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma.  Onco Targets Ther 2017; 10:3965-3969. 
8. Takeda M, Okamoto I, Nakagawa K. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung Cancer 2015; 88:74-79.
9. El Naggar EE, Mohamed EA, Borg TM, El-Sheakh AR, Hamed MF. Colon targeting of naringin for enhanced cytoprotection against indomethacin-induced colitis in rabbits. Drug Des Devel Ther 2020; 14:677-696. 
10. Hassan RA, Hozayen WG, Abo Sree HT, Al-Muzafar HM, Amin KA, Ahmed OM. Naringin and hesperidin counteract diclofenac-induced hepatotoxicity in male Wistar rats via their anti-oxidant, anti-inflammatory, and antiapoptotic activities. Oxid Med Cell Longev 2021; 2021:9990091.
11. Caglayan C, Temel Y, Kandemir FM, Yildirim S, Kucukler S. Naringin protects against cyclophosphamide-induced hepatotoxicity and nephrotoxicity through modulation of oxidative stress, inflammation, apoptosis, autophagy, and DNA damage. Environ Sci Pollut Res Int 2018; 25:20968-20984. 
12. Akamo AJ, Rotimi SO, Akinloye DI, Ugbaja RN, Adeleye OO, Dosumu OA, et al. Naringin prevents cyclophosphamide-induced hepatotoxicity in rats by attenuating oxidative stress, fibrosis, and inflammation. Food Chem Toxicol 2021; 153:112266.
13. Shirani K, Yousefsani BS, Shirani M, Karimi G. Protective effects of naringin against drugs and chemical toxins induced hepatotoxicity: A review. Phytother Res 2020; 3:1734-1744. 
14. Fu JN, Liu SC, Chen Y, Zhao J, Lu N, Ma T. Forsythiaside a alleviates aipopolysaccharide-induced acute liver injury through inhibiting endoplasmic reticulum stress and NLRP3 inflammasome activation. Biol Pharm Bull. 2023 ;46:979-986. 
15. Luo N, Chen GB, Zhang T, Zhao J, Fu JN, Lu N, et al. Genipin attenuates sepsis-induced splenocyte apoptosis via the inhibition of endoplasmic reticulum stress. Biol Pharm Bull 2023; 46:187-193.
16. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008; 47:1363-1370.
17. Li W, Xiao H, Wu H, Xu X, Zhang Y. Organophosphate pesticide exposure and biomarkers of liver injury/liver function. Liver Int. 2022; 42:2713-2723.
18. Luo P, Yan H, Du J, Chen X, Shao J, Zhang Y, et al. PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1). Autophagy 2021; 17:3221-3237. 
19. AlRasheed H, Almomen A, Aljohar HI, Arafah M, Almotawa RY, Alossaimi MA, et al. Aspartames alter pharmacokinetics parameters of erlotinib and gefitinib and elevate liver enzymes in Wistar rats. Pharmaceuticals (Basel) 2022; 15:1400-1409.
20. Oda S, Miyazaki N, Tsuneyama K, Yokoi T. Exacerbation of gefitinib-induced liver injury by glutathione reduction in mice. J Toxicol Sci 2020; 45:493-502. 
21. Ge B, Sang R, Wang W, Yan K, Yu Y, Kong L, et al. Protection of taraxasterol against acetaminophen-induced liver injury elucidated through network pharmacology and in vitro and in vivo experiments. Phytomedicine 2023; 116:154872. 
22. Zhang Y, Cai Y, Zhang SR, Li CY, Jiang LL, Wei P, et al. Mechanism of hepatotoxicity of first-line tyrosine kinase inhibitors: Gefitinib and afatinib. Toxicol Lett 2021; 343:1-10. 
23. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462. 
24. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998; 281:1309-1312.
25. Kuida K, Haydar TF, Kuan CY, Gu Y, Taya C, Karasuyama H, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell. 1998; 94:325-337. 
26. Lakhani SA, Masud A, Kuida K, Porter GA, Booth CJ, Mehal WZ, et al. Caspases 3 and 7: Key mediators of mitochondrial events of apoptosis. Science 2006; 311:847-851. 
27. Xu H, Shen X, Li X, Yang X, Chen C, Luo D. The natural product dehydrocurvularin induces apoptosis of gastric cancer cells by activating PARP-1 and caspase-3. Apoptosis 2023; 28:525-538.
28. Rabinowitz JD, White E. Autophagy and metabolism. Science. 2010; 330:1344-1348.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 18 June 2024

Files

Share

How to cite

Statistics